An intravitreal device providing sustained release of cyclosporine and dexamethasone

References

• Chandler D. B., Rozakis G., de Juan E. J., Machemer R. The effect of triamcinolone acetonide on a refined experimental model of proliferative vitreoretinopathy. Am. J. Ophthalmol. 1985; 99: 686–690
   PubMedGoogle Scholar
• Chandler D. B., Hida T., Sheta S., Proia A. D., Machemer R. Improvement in efficacy of cortico-steroid therapy in an animal model of proliferative vitreoretinopathy by pretreatment. Graefe's Arch. Clin. Exp. Ophthalmol. 1987; 225: 259–265
   PubMedGoogle Scholar
• Khawly J. A., Saloupis P., Hatchell D. L., Machemer R. Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy. Graefe's Arch. Clin. Exp. Ophthalmol. 1991; 229: 464–467
   PubMedGoogle Scholar
• Lemor M., Yeo J. H., Glaser B. M. Oral colchicine for the treatment of experimental traction retinal detachment. Arch. Ophthalmol. 1986; 104: 1226–1229
   PubMed Web of Science ®Google Scholar
• Tano Y., Chandler D., Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am. J. Ophthalmol. 1980; 90: 810–816
   PubMed Web of Science ®Google Scholar
• Wiedemann P., Kirmani M., Santana M., Sorgente N., Ryan S. J. Control of experimental massive periretinal proliferation by daunomycin: dose response relation. Graefe's Arch. Clin. Exp. Ophthalmol. 1983; 220: 233–235
   PubMed Web of Science ®Google Scholar
• Wiedemann P., Sorgente N., Bekhor C., Patterson R., Tran T., Ryan S. J. Daunomycin in the treatment of experimental proliferative vitreoretinopathy. Effective doses in vitro and in vivo. Invest. Ophthalmol. Vis. Sci. 1985; 26: 719–725
   PubMed Web of Science ®Google Scholar
• Machemer R., Sugita G., Tano Y. Treatment of intraocular proliferations with intravitreal steroids. Tr. Am. Ophth. Soc. 1979; 77: 171–178
   PubMedGoogle Scholar
• Tano Y., Sugita G., Abrams G., Machemer R. Inhibition of intraocular proliferations with intravitreal corti-costeroids. Am. J. Ophthalmol. 1980; 89: 131–136
   PubMed Web of Science ®Google Scholar
• Ruhmann A., Berliner D. Effect of steroids on growth of mouse fibroblasts in vitro. Endocrinology 1965; 76: 916–927
   PubMedGoogle Scholar
• Grossfield H., Ragan C. Action of hydrocor-tisone on cells in tissue culture. Proc. Soc. Exp. Biol. Med. 1954; 86: 63–68
   PubMedGoogle Scholar
• Barr C. C., Blumenkranz M. S. New substances in the treatment of proliferative vitreoretinopathy. Ophthalmol. Clin. North America 1989; 2: 187–198
   Google Scholar
• Hui Y. N., Liang H. C., Cai Y. S., Kirchhof B., Heimann K. Corticosteroids and daunomycin in the prevention of experimental proliferative vitreoretinopathy induced by macrophages. Graefe's Arch. Clin. Exp. Ophthalmol. 1993; 231: 109–114
   PubMed Web of Science ®Google Scholar
• Stahl J. G., Miller D. B., Conway B. P., Campochiaro P. A. Dexamethasone and indomethacin attenuate cryopexy induced breakdown of the blood-retinal barrier. Graefe's Arch. Clin. Exp. Ophthalmol. 1987; 225: 418–420
   PubMedGoogle Scholar
• Wilson C. A., Berkowitz B. Z., Sato Y., Ando N., Handa J. T., de Juan E. J. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol. 1992; 110: 1155–1159
   PubMed Web of Science ®Google Scholar
• Nussenblatt R. B., Dinning W. J., Fujikawa L. S., Chan C. C., Palestine A. G. Local cyclosporine therapy for experimental autoimmune uveitis in rats. Arch. Ophthalmol. 1985; 103: 1559–1562
   PubMed Web of Science ®Google Scholar
• Charteris D. G., Hiscott P., Robey H. L., Gregor Z. I., Lightman S. L., Grierson I. Inflammatory cells in proliferative vitreoretinopathy subretinal membranes. Ophthalmology 1993; 100: 43–46
   PubMed Web of Science ®Google Scholar
• Charteris D. G., Hiscott P., Grierson I., Lightman S. L. Proliferative vitreoretinopathy. Lymphocytes in epiretinal membranes. Ophthalmology 1992; 99: 1364–1367
   PubMed Web of Science ®Google Scholar
• Capone A., Aaberg T. M. Intermediate uveitis. Principles and Practice of Ophthalmology: Clinical Practice, D. M. Albert, F. A. Jakobiec. W.B. Saunders Co., Philadelphia 1994; 437
   Google Scholar
• Deray G., Benhmida M., Le-Hoang P. L., Maksud P., Aupetit B., Baumelou A., Jacobs C. Renal function and blood pressure in patients receiving long-term, low-dose cyclosporine therapy for idiopathic autoimmune uveitis. Ann. Intern. Med. 1992; 117: 578–583
   PubMed Web of Science ®Google Scholar
• Nussenblatt R., Palestine A. Cyclosporine: immunology, pharmacology and therapeutic uses. Surv. Ophthalmol. 1986; 31: 159–169
   PubMed Web of Science ®Google Scholar
• BenEzra D., Maftzir G. Ocular penetration of cyclosporine A in the rat eye. Arch. Ophthalmol. 1990; 108: 584–587
   PubMed Web of Science ®Google Scholar
• BenEzra D., Maftzir G. Ocular penetration of cyclosporin A: the rabbit eye. Invest. Ophthalmol. Vis. Sci. 1990; 31: 1362–1366
   PubMed Web of Science ®Google Scholar
• BenEzra D., Maftzir G., de Courten C., Timonen P. Ocular penetration of cyclosporin A III: the human eye. Br. J. Ophthalmol. 1990; 74: 350–352
   PubMed Web of Science ®Google Scholar
• Pearson P. A., Jaffe G. J., Martin D. F., Ashton P. Evaluation of a sustained delivery system providing long term release of cyclosporine. Arch. Ophthalmol.
   Google Scholar
• Hainsworth D. P., Conklin J. D., Baker C. S., Ashton P. Evaluation of sustained release intravitreal dexamethasone. J. Ocular. Pharm.
   Google Scholar
• Cheng C. K., Berger A. S., Pearson P. A., Ashton P., Jaffe G. J. Intravitreal sustained-release dexamethasone device in the treatment of experimental uveitis. Invest. Ophthalmol. Vis. Sci. 1995; 36: 442–453
   PubMed Web of Science ®Google Scholar
• Claman H. N. Glucocorticosteroids I: anti-inflammatory mechanisms. Hosp. Pract. 1983; 18: 123–134
   Web of Science ®Google Scholar
• Smith T. J., Pearson P. A., Blandford D. L., Brown J. D., Goins K. A., Hollins J. L., Schmeisser E. T., Glavinos P., Baldwin L. B., Ashton P. Intravitreal sustained-release ganciclovir. Arch. Ophthalmol. 1992; 110: 255–258
   PubMed Web of Science ®Google Scholar
• Law will T. Practical rabbit electroretinography. Am. J. Ophthalmol. 1972; 74: 135–141
   PubMedGoogle Scholar
• Spivey B. E., Pearlman J. T. Day-to-day variations in the ERG of humans and rabbits. Am. J. Ophthalmol. 1953; 55: 1013–1020
   Google Scholar
• Tresher R. J., Ehrenberg M., Machemer R. Gas-mediated vitreous compression: An experimental alternative to mechanized vitrectomy. Graefe's Arch. Clin. Exp. Ophthalmol. 1984; 221: 192–198
   PubMedGoogle Scholar
• Cunha-Vaz J. G., Travassos A. Breakdown of the blood-retinal barriers and cyctoid macular edema. Surv. Ophthalmol. 1984; 28: 485–492
   PubMed Web of Science ®Google Scholar
• Lafferty K. J., Borel J. F., Hodgkin P. Cyclosporine-A (CsA): models for the mechanism of action. Transplant. Proc. 1983; 15: 2242–2247
   Web of Science ®Google Scholar
• Floman N., Zor U. Mechanism of steroid action in ocular inflammation: Inhibition of prostaglandin production. Invest. Ophthalmol. Vis. Sci. 1977; 16: 69–73
   PubMed Web of Science ®Google Scholar
• Naveh N., Weissman C. Corticosteroid treatment of laser retinal damage affects prostaglandin E2 response. Invest. Ophthalmol. Visual Sci. 1990; 31: 9–13
   PubMedGoogle Scholar
• Flower R. J., Blackwell G. J. Anti-inflammatory steroids induce biosynthesis of a phospholipase A2 inhibitor which prevents prostaglandin generation. Nature 1979; 278: 456–459
   PubMed Web of Science ®Google Scholar
• Lewis G. D., Campbell W. B., Johnson A. R. Inhibition of prostaglandin synthesis by glucocorticoids in human endothelial cells. Endocrinology 1986; 119: 62–69
   PubMed Web of Science ®Google Scholar
• Lee S. W., Tsou A. P., Chan H., Thomas J., Petrie K., Eugui E. M., Allison A. C. Glucocorticoids selectively inhibit the transcription of the interleukin lb gene and decrease the stabiligy of interleukin lb mRNA. Proc. Natl. Acad. Sci. USA 1988; 85: 1204–1208
   PubMed Web of Science ®Google Scholar
• Knudsen P. I., Dinarello C. A., Strom T. B. Glucocorticoids ingibit transcriptional and post-transcrip-tional expression of interleukin 1 in U937 cells. J. Immunol. 1987; 139: 4129–4134
   PubMed Web of Science ®Google Scholar
• Grabstein K., Dower S., Gillis S., Urdal D., Larsen A. Expression of interleukin 2, innterferon-g, and the IL-2 receptor by human peripheral blood lymphocytes. J. Immunol. 1986; 136: 4503–4508
   PubMed Web of Science ®Google Scholar
• Arya S. K., Wong-Staal F., Gallo R. C. Dexamethasone-mediated inhibition of human T cell growth factor and g-interferon messenger RNA. J. Immunol. 1984; 133: 273–276
   PubMed Web of Science ®Google Scholar
• Culpepper J. A., Lee F. Regulation of IL-3 by glucocorticoids in cloned murine T lymphocytes. J. Immunol. 1985; 135: 3191–3197
   PubMed Web of Science ®Google Scholar
• Kelso A., Munck A. Glucocorticoid inhibition of lymphokine secretion by alloreactive T lymphocyte clones. J. Immunol. 1984; 133: 784–791
   PubMed Web of Science ®Google Scholar
• Lam T. T., Edward D. P., Zhu X., Tso M. O. M. Transscleral Iontophoresis of Dexamethasone. Arch. Ophthalmol 1989; 107: 1368–1371
   PubMedGoogle Scholar
• Calne R. Y., White D. J. G. The use of cyclo-sporin A in clinical organ grafting. Ann. surg. 1982; 196: 330–336
   PubMed Web of Science ®Google Scholar
• Graham R. O., Peyman G. A. Intravitreal injection of dexamethasone: treatment of experimentally induced endophthalmitis. Arch. Ophthalmol. 1974; 92: 149–154
   PubMed Web of Science ®Google Scholar
• Kwak H. W., D'Amico D. J. Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch. Ophthalmol. 1992; 110: 259–266
   PubMed Web of Science ®Google Scholar
• BenEzra D., Nussenblatt R. B., Timonen P. Optimal use of Sandimmun in Endogenous Uveitis. Springer-Verlag, New York 1988; 17
   Google Scholar
• Grisolano J., Peyman G. A. Retinal toxicity study of intravitreal cyclosporin. Ophthalmic Surg. 1986; 17: 155–156
   PubMedGoogle Scholar
• Sanborn G. E., Anand R., Torti R. E., Nightingale S. D., Cal S. X., Yates B., Ashton P., Smith T. Sustained-release ganciclovir therapy for treatment of cyto-megalovirus retinitis. Arch. Ophthalmol. 1992; 110: 188–195
   PubMed Web of Science ®Google Scholar
• Anand R., Nightingale S. D., Fish R. H., Smith T. J., Ashton P. Control of cytomegalovirus retinitis using sustained release of intraocular ganciclovir. Arch. Ophthalmol. 1993; 111: 223–227
   PubMed Web of Science ®Google Scholar